CHAPTER 1 - MARKET SUMMARY
Market Overview
The India Point-of-Care Testing (POCT) Market functions through recurring consumables, including strips, cartridges, cassettes and reagents, paired with meters, readers and compact analyzers. Demand is anchored in high-frequency screening and monitoring: the National NCD Portal had enrolled 74.97 crore beneficiaries by December 2025, creating a broad funnel for near-patient glucose, HbA1c, lipid and cardiovascular testing.
Commercial demand is concentrated in major hospital and diagnostic clusters across Maharashtra, Karnataka, Tamil Nadu, Telangana, Delhi NCR and Gujarat, while public procurement expands the addressable rural base. India had 1,81,873 operational Ayushman Arogya Mandirs by November 2025, with cumulative footfall of 494.71 crore, making primary-care sites a nationally distributed testing channel rather than a metro-only opportunity.
Market Value
USD 1,140 million
2025
Dominant Region
South India
Dominant Segment
Infectious Disease Rapid Tests
fastest growing
Total Number of Players
85
Future Outlook
The India Point-of-Care Testing (POCT) Market is projected to increase from USD 1,140 million in 2025 to USD 1,955 million by 2031, reflecting a forecast CAGR of 9.41% compared with a 7.34% historical CAGR during 2020-2025. Growth will be led by recurring consumables, decentralized molecular assays, higher-value cardiac and coagulation panels, and broader self-testing. Public primary-care infrastructure, 41.93 crore cumulative teleconsultations through Ayushman Arogya Mandirs by November 2025, and expanding digital record linkage will support referral-based testing and same-visit treatment decisions.
By 2031, test volume is expected to reach approximately 1,280 million test equivalents, up from 815 million in 2025, while the blended value per test rises as molecular, immunofluorescence and connected analyzer formats gain share. Glucose monitoring will remain the largest recurring pool, but infectious-disease and cardiometabolic testing will deliver the strongest incremental revenue. Domestic manufacturers can capture value through localized reagents, instrument rental models and public tenders, while multinational suppliers retain advantages in assay menus, quality systems and hospital connectivity. The principal execution risks are price compression, operator training and lot-to-lot quality control.
9.41%
Forecast CAGR
$1,955 Mn
2030 Projection
Base Year
2025
Historical Period
2020-2025
Forecast Period
2026-2031
Historical CAGR
7.34%
CHAPTER 2 - SCOPE OF REPORT
Scope of the Market
CHAPTER 3 - Key Stakeholders
Key Target Audience
Key stakeholders who can leverage from this market analysis for investment, strategy, and operational planning.
Investors
CAGR, consumable recurrence, localization, regulatory risk, exit potential
Corporates
analyzer placement, channel reach, tender access, portfolio profitability
Government
screening coverage, domestic value addition, quality, health access
Operators
throughput, turnaround time, connectivity, quality control, uptime
Financial institutions
working capital, contract tenure, cash conversion, covenant resilience
CHAPTER 4 - Market Size & Growth
Market Size, Growth Forecast and Trends
This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers.
Historical & Projected Market Size ($ Million)
Year-over-Year Growth Rate (%)
Market Value vs Volume Growth (%)
Historical Market Performance (2020-2025)
Market value expanded from USD 800 million in 2020 to USD 1,140 million in 2025, producing a 7.34% historical CAGR. The strongest annual increase occurred in 2021 at 7.75%, as pandemic-era rapid testing accelerated channel formation and consumer familiarity. Growth moderated to 6.61% in 2022 as acute COVID-19 demand normalized, then recovered through chronic-disease monitoring, emergency testing and public screening. Test volume rose from approximately 605 million to 815 million equivalents, while the blended value per test improved modestly as instrument-based immunoassay and molecular formats gained adoption.
Forecast Market Outlook (2026-2031)
Market value is forecast to reach USD 1,955 million by 2031, representing a 9.41% CAGR from 2025. Annual expansion is expected to remain near 9.4%, supported by decentralized molecular platforms, connected analyzers, recurring consumable pull-through and home testing. Test volume is projected to reach approximately 1,280 million equivalents, a 7.82% volume CAGR, while mix improvement contributes the balance of value growth. The terminal-year outcome assumes broader primary-care procurement, tighter quality governance, improved domestic reagent production and faster referral pathways between community sites, clinicians and confirmatory laboratories.
CHAPTER 5 - Market Data
Market Breakdown
The India Point-of-Care Testing (POCT) Market is moving from stand-alone rapid kits toward connected, consumable-led diagnostic platforms. For CEOs and investors, value creation increasingly depends on test throughput, analyzer placement, local reagent economics and the ability to maintain quality across decentralized care settings.
Year | Market Size (USD Mn) | YoY Growth (%) | Test Volume (Mn Equivalents) | Connected Analyzer Base (000 Units) | Domestic Value Addition (%) | Period |
|---|---|---|---|---|---|---|
| 2020 | $800 Mn | +- | 605 | 32 | Forecast | |
| 2021 | $862 Mn | +7.75% | 662 | 37 | Forecast | |
| 2022 | $919 Mn | +6.61% | 701 | 42 | Forecast | |
| 2023 | $988 Mn | +7.51% | 744 | 49 | Forecast | |
| 2024 | $1,058 Mn | +7.09% | 782 | 55 | Forecast | |
| 2025 | $1,140 Mn | +7.75% | 815 | 62 | Forecast | |
| 2026 | $1,247 Mn | +9.39% | 876 | 70 | Forecast | |
| 2027 | $1,364 Mn | +9.38% | 943 | 79 | Forecast | |
| 2028 | $1,492 Mn | +9.38% | 1,018 | 89 | Forecast | |
| 2029 | $1,632 Mn | +9.38% | 1,099 | 101 | Forecast | |
| 2030 | $1,786 Mn | +9.44% | 1,185 | 114 | Forecast | |
| 2031 | $1,955 Mn | +9.46% | 1,280 | 130 | Forecast |
Test Volume
815 million test equivalents, 2025, India. High-frequency glucose and rapid infectious-disease testing create repeat-consumable economics; 1,81,873 Ayushman Arogya Mandirs were operational by November 2025, broadening community-level throughput.
Connected Analyzer Base
62,000 units, 2025, India. Connectivity improves operator control, result traceability and hospital integration; the ABDM dashboard reports more than 95 crore linked health records, strengthening the infrastructure for interoperable diagnostic data.
Domestic Value Addition
34%, 2025, India. Local reagent and cartridge manufacturing can expand gross margin and tender competitiveness; the medical-device PLI program had commissioned 19 greenfield projects and enabled 44 previously imported products by September 2024.
CHAPTER 6 - Segmentation
Market Segmentation Framework
Comprehensive analysis across key dimensions providing insights into market structure, consumer preferences, and distribution patterns.
No of Segments
7
Dominant Segment
Product Type
Fastest Growing Segment
Technology
Product Type
Care Setting
End User
Disease Area
Channel
Technology
Geography
Key Segmentation Takeaways
Comprehensive analysis across all extracted segmentation dimensions providing insights into market structure, consumer preferences, and distribution patterns.
Product Type
Product mix determines recurring revenue, analyzer utilization and customer retention. Glucose monitoring products remain the largest repeat-purchase pool because strips and lancets generate frequent replenishment across household and clinical use. Infectious disease rapid tests contribute episodic but high-volume demand, while cardiometabolic and coagulation panels command higher prices in emergency, critical-care and specialty-clinic workflows.
Technology
Technology is the fastest-growing dimension as buyers shift from visual lateral-flow kits toward reader-assisted immunoassays, electrochemical biosensors and portable molecular systems. Molecular amplification is the strongest expansion pocket because it combines near-laboratory sensitivity with decentralized deployment. Growth depends on cartridge affordability, battery-backed operation, connectivity, operator training and quality assurance across public and private care networks.
CHAPTER 7 - Regional Analysis
Regional Analysis
India ranks third among the selected Asia-Pacific peer markets by 2025 POCT revenue, behind China and Japan but ahead of South Korea and Indonesia. Its strategic position reflects a large screening population, lower per-capita healthcare spending and faster decentralization of primary diagnostics than mature markets. Country estimates are normalized to the report's product-revenue scope.
Focus Country Ranking
3rd
Focus Country Market Size
USD 1,140 Mn (2025)
Focus Country CAGR (2026-2031)
9.41%
Focus Country Ranking
3rd
Focus Country Market Size
USD 1,140 Mn (2025)
Focus Country CAGR (2026-2031)
9.41%
Regional Analysis (Current Year)
Market Position
India's USD 1,140 million market ranks third, with scale supported by 1,81,873 operational Ayushman Arogya Mandirs and a nationwide screening network that expands access beyond hospital clusters.
Growth Advantage
India's 9.41% CAGR exceeds Japan's 8.10% and South Korea's 7.80%, but trails China and Indonesia, positioning India as a scaled mid-high-growth challenger rather than the region's fastest market.
Competitive Strengths
India combines a 1.4-billion-plus population, low USD 92 per-capita health spending and 95 crore-plus linked digital health records, favoring affordable, connected and locally manufactured POCT platforms.
CHAPTER 8 - INDUSTRY ANALYSIS
Growth Drivers, Challenges & Opportunities
Comprehensive analysis of key factors shaping the India Point-of-Care Testing (POCT) Market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution, and consumer segments.
Growth Drivers
Decentralized Primary-Care Diagnostics
- Cumulative AAM footfall reached 494.71 crore visits (2025, India), creating recurring demand for glucose, pregnancy, hemoglobin, infectious-disease and triage testing close to patients.
- Public facilities offer 14 tests at sub-centres and 63 tests at primary health centres (2025, India), making tender access and low-cost consumables central to supplier growth.
- AAM teleconsultations reached 41.93 crore consultations (2025, India), allowing rapid-test results to trigger remote clinical decisions and expanding value for interoperable devices.
Chronic-Disease Screening and Monitoring
- More than 8.64 crore patients were under treatment for hypertension and diabetes (2025, India), supporting repeat glucose, HbA1c, lipid and renal-risk testing.
- AAMs had conducted 94.56 crore diabetes screenings (February 2025, India), indicating the scale advantage available to suppliers with robust strips, readers and field-service networks.
- The ICMR-INDIAB national study estimated 101 million adults with diabetes (2021 data, India), making long-term monitoring a durable consumable profit pool rather than a one-time screening event.
Infectious-Disease and Acute-Care Testing
- India's TB burden creates a large addressable pool for cartridge-based molecular testing, with two TB deaths every three minutes (latest WHO India statement, India) reinforcing the clinical value of earlier diagnosis.
- CDSCO post-market guidance identifies HIV, hepatitis, syphilis, malaria, dengue and cardiac-marker IVDs as Class C or D examples, expanding regulated demand across six major high-risk test categories (2022 guidance, India).
- Molbio reports 40 million-plus lives touched across 85-plus countries (2026, company operations), demonstrating that India-developed decentralized molecular platforms can scale domestically and internationally.
Market Challenges
Regulatory Classification and Evidence Burden
- Class C and D products require stronger clinical-performance and post-market controls, raising launch cost for infectious, cardiac and blood-screening assays across two higher-risk classes (2024 guidance, India).
- The Medical Devices Rules took effect on 1 January 2018 (MDR 2017, India), but state-level procurement and hospital accreditation can still create non-uniform evidence and documentation expectations.
- ISO 15189:2022 now integrates POCT governance within laboratory quality systems, requiring operator authorization, traceability and risk management across one unified accreditation framework (2022 standard, global).
Affordability, Tender Pricing and Reimbursement Pressure
- Public procurement prioritizes low per-test cost across 1,81,873 AAMs (2025, India), pressuring suppliers to localize consumables and control distributor and service costs.
- Glucose and lateral-flow categories face intense commoditization, while higher-value molecular and immunoassay products must demonstrate faster decisions within same-visit care pathways (2026, global POCT practice).
- Price-sensitive buyers often separate analyzer acquisition from recurring reagent budgets, increasing working-capital exposure over multi-year instrument placement contracts (2025, India market model) and favoring well-capitalized vendors.
Operator Variability and Quality-Control Gaps
- India's AAM network delivers 12 packages of comprehensive primary care (2025, India), so staff time for calibration, controls and documentation competes with broader clinical responsibilities.
- Visual rapid tests remain vulnerable to timing and interpretation differences, making reader-assisted formats attractive but adding hardware, maintenance and training across four major care-setting categories (2025, India market scope).
- Connectivity failures can interrupt patient matching and result transfer despite 95 crore-plus linked health records (2026, India), requiring offline capability, audit trails and secure synchronization.
Market Opportunities
Localized Reagents, Cartridges and Analyzer Assembly
- Local reagent and cartridge production can improve gross margin, tender resilience and supply continuity as 19 greenfield projects were commissioned (September 2024, India).
- Manufacturers, contract producers and component suppliers benefit from recurring consumables, while hospitals gain lower landed cost across 44 previously imported products entering production (2024, India).
- The opportunity requires validated domestic enzymes, membranes, antibodies, plastics and electronics plus quality systems capable of supporting Class A through D IVD portfolios (MDR 2017, India).
Connected POCT and Managed Testing Networks
- Vendors can monetize software, quality dashboards, operator credentialing and fleet management alongside assays, converting one-time hardware sales into recurring multi-year service revenue (2026, India opportunity model).
- Hospitals and diagnostic chains benefit from automatic LIS or HIS transmission, reducing manual entry and supporting same-visit clinical action (2026, connected POCT practice).
- Scale requires common data standards, cybersecurity, offline synchronization and integration with ABHA identifiers across 79.75 crore ABHA IDs created by July 2025 (India).
Portable Molecular Testing for Public-Health Programs
- Investors and manufacturers can capture cartridge pull-through from TB, respiratory, hepatitis, HPV and antimicrobial-resistance programs, building on 40 million-plus lives reached by Molbio (2026, company operations).
- Public buyers benefit when portable systems reduce sample transport and loss to follow-up, especially across 1,81,873 primary-care facilities (2025, India).
- Commercial scale requires battery-backed platforms, room-temperature cartridges, external quality assurance and procurement models that fund both instruments and multi-disease assay menus (2026, India opportunity model).
CHAPTER 9 - Competitive Landscape
Competitive Landscape Overview
Competition is moderately concentrated across multinational platform leaders and Indian diagnostic manufacturers, with entry barriers created by assay validation, regulatory licensing, installed-base service coverage, procurement access and recurring consumable economics.
Market Share Distribution
Top 5 Players
Market Dynamics
8 new entrants in the past 5 years, indicating strong market attractiveness and growth potential.
Company Name | Market Share | Headquarters | Founding Year | Core Market Focus |
|---|---|---|---|---|
Abbott Laboratories | - | Abbott Park, United States | 1888 | Glucose monitoring, rapid infectious-disease tests, i-STAT blood analysis and molecular POCT |
Roche Diagnostics | - | Basel, Switzerland | 1896 | Coagulation, blood glucose, cardiac markers, urinalysis and connected POCT management |
Siemens Healthineers | - | Erlangen, Germany | 1896 | Blood gas, urinalysis, diabetes, cardiac and critical-care point-of-care systems |
Danaher Corporation | - | Washington, D.C., United States | 1969 | Cepheid near-patient molecular diagnostics and Beckman Coulter clinical testing platforms |
Becton, Dickinson and Company | - | Franklin Lakes, United States | 1897 | Rapid infectious-disease, immunoassay and specimen-management solutions |
bioMérieux | - | Marcy-l'Étoile, France | 1963 | Infectious-disease, syndromic molecular and acute-care diagnostic solutions |
Trivitron Healthcare | - | Chennai, India | 1997 | Domestic IVD analyzers, rapid tests, reagents and distributed diagnostic systems |
Transasia Bio-Medicals | - | Mumbai, India | 1979 | Clinical chemistry, hematology, immunology, urinalysis and compact diagnostics |
Molbio Diagnostics | - | Verna, Goa, India | 2000 | Truenat portable molecular testing for TB and other infectious diseases |
Meril Diagnostics | - | Vapi, Gujarat, India | 2006 | Rapid tests, immunoassay, hematology, clinical chemistry and POCT systems |
Cross Comparison Parameters
The report provides detailed cross-comparison of key players across 10 performance parameters to identify competitive strengths and weaknesses.
Installed Analyzer Base
Annual Test Throughput
India POCT Revenue Growth
Consumables Gross Margin
Analysis Covered
Market Share Analysis:
Compares India revenue concentration across multinational and domestic diagnostic suppliers.
Cross Comparison Matrix:
Benchmarks installed base, throughput, growth and consumable economics consistently.
SWOT Analysis:
Assesses portfolio depth, localization, service reach and regulatory execution risks.
Pricing Strategy Analysis:
Evaluates analyzer placement, reagent rental, tender and retail price models.
Company Profiles:
Reviews India presence, product focus, headquarters and operating capabilities.
CHAPTER 10 - REPORT TOC
Table of Contents
Phase 1Market Assessment Phase
11
Chapters
Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts.
Phase 2Go-To-Market Strategy Phase
15
Chapters
Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook.
Complete Report Coverage
201+ detailed sections covering every aspect of the market
143
Assessment Sections
58
Strategy Sections
CHAPTER 11 - Our Approach
Research Methodology
Desk Research
- Reviewed CDSCO IVD licensing classifications
- Mapped public diagnostic procurement programs
- Analyzed company POCT product portfolios
- Benchmarked disease screening and volumes
Primary Research
- Interviewed diagnostic business unit heads
- Consulted hospital laboratory directors nationwide
- Engaged public procurement program managers
- Surveyed distributors and pharmacy buyers
Validation and Triangulation
- Validated across 408 stakeholder interviews
- Reconciled instrument and consumable revenues
- Cross-checked volumes against screening programs
- Tested pricing through channel interviews
CHAPTER 12 - FAQ
FAQs
Still have questions?
Our research team is here to help you find the right solution
CHAPTER 13 - Related Research
Explore Related Reports
Expand your market intelligence with complementary research across regions and adjacent markets.
Regional/Country ReportsRelated market analysis across key regions
Related market analysis across key regions
- Indonesia Point-of-Care Testing (POCT) Market
- Vietnam Point-of-Care Testing (POCT) Market
- Thailand Point-of-Care Testing (POCT) Market
- Malaysia Point-of-Care Testing (POCT) Market
- Philippines Point-of-Care Testing (POCT) Market
Adjacent ReportsRelated markets and complementary research
Related markets and complementary research
- South Korea Teleconsultation Services Market
- South Africa Digital Health Records Market
- Malaysia Infectious Disease Rapid Tests Market
- Malaysia Decentralized Molecular Assays Market
- Japan Cardiometabolic Testing Market
500+
Market Research Reports
50+
Countries Covered
15+
Industry Verticals